Alto Neuroscience, Inc. (ANRO)

NYSE Pharmaceutical Pharmaceutical Preparations SIC: 2834

Pipeline Grade

Financial Position (from SEC Filings)

$264.3M

Cash & Equivalents

$27.1M

Quarterly Burn Rate

29 mo

Est. Cash Runway

$929M

Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

NCT #	Title	Phase	Status	Enrollment
NCT06107426	Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parki...	OTHER	Active Not Recruiting	427
NCT06543914	Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine	OTHER	Active Not Recruiting	1,314
NCT01848561	A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)	OTHER	Active Not Recruiting	8,250
NCT06553027	To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications	PHASE3	Active Not Recruiting	330
NCT05702034	A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR...	PHASE3	Active Not Recruiting	12,532
NCT05531526	Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participant...	PHASE3	Active Not Recruiting	1,535
NCT05814627	Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab i...	PHASE3	Active Not Recruiting	487
NCT06680830	A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's...	PHASE2	Recruiting	150

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for ANRO.

All SEC filings for Alto Neuroscience, Inc. on EDGAR.

View all upcoming FDA catalysts across all biotech companies.